Member Info for Borsaci06

connections &
Emergex just doing that
happy days :)

@JamesTodaroMD
1/ There is growing evidence that T-cell immunity allows populations to reach herd immunity once only 10-20% are infected with SARS-CoV-2.
This would explain why a highly transmissible virus in densely populated areas peaked at 10-20% infected regardless of lockdowns or masks.
https://twitter.com/JamesTodaroMD/status/1292873236716433416

@LucLoja
You should have a chat with our portfolio company Emergex (https://emergexvaccines.com) in the UK. Working on CD8 T-cell primers. Happy to refer
https://twitter.com/LucLoja/status/1298114916918804480

they are also involved with " The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund "

RDIF and Dr. Reddy’s to cooperate on clinical trials and supply of 100 million doses of Sputnik V vaccine to India

https://www.drreddys.com/media/904781/sputnikv-india_dr-reddys.pdf

another after 87 days

September 3,2020
Dr. Reddy's Laboratories announces the launch of Methylphenidate Hydrochloride Extended-ReleaseTablets USP,
in the U.S. Market

The Concerta®brand and generic market had U.S. sales of approximately $1.159 billionMAT for the most recent twelve months ending in June2020 according to IQVIAHealth

https://www.drreddys.com/media/904777/press-release-_-methylphenidate-er-concerta.pdf

<<< That is lightning speed for a biotech company >>>

"" The Tecfidera®brand and generic market had U.S. sales of approximately $3.8 billion MAT for the mostrecent twelve months ending in June2020according to IQVIAHealth ""

<<< we signed two collaborations in that period in only 3.5 months >>>

what a surprising coincidence !!!!

* 08 June 2020
Midatech enters into research collaboration with Dr Reddy's Laboratories Ltd (Dr Reddy's")

https://www.investegate.co.uk/midatech-pharma-plc--mtph-/rns/research-collaboration-with-dr-reddy-s/202006080700061811P/

After 110 days,
Dr Reddy's announced following

* September 26,2020
Dr. Reddy's Laboratories announces the launch of Dimethyl Fumarate Delayed-Release Capsules in the U.S. Market
Delayed-Release Capsules,approved by the U.S. Food andDrug Administration (USFDA)

https://www.drreddys.com/media/904789/pressreleasedimethylfumarateg.pdf

Grammar is a set of rules about the structure of language. Grammer is a proper noun that refers to a particular American community, or the name of a person

https://www.google.com/search?client=firefox-b-d&q=Grammer

Helen3

£5M payment to Synairgenplus percentage of all future partnering revenues
The revised agreement fixes Synairgen’s interest across all fibrotic indications at circa 17% of all partnering proceeds.

https://www.synairgen.com/wp-content/uploads/2019/01/14-December-2017_Update-on-LOXL2-Programme-and-Collaboration-with-Pharmaxis.pdf

17% X 35,000,000,000 = 5,950,000,000 NASH / Liver Fibrosis
17% X 3,500,000,000 = 595,000,000 Pulmonary fibrosis (IPF)

remember this = LOXL2 inhibitors

LOXL-2
Chronic fibrosis -NASH,IPF, CKD

PXS-5382/PXS5338;
Phase 1 trials in 2 compounds complete.
Commercial partnering process in progress.

* NASH / Liver Fibrosis;
$35b
Deutsche Bank market forecast for 2025

* Pulmonary fibrosis (IPF);
$3.5b
iHealthcareanalyst. Incmarket forecast for 2021

* Kidney fibrosis
* Cardiac fibrosis
http://www.pharmaxis.com.au/assets/Documents/pdf/02020/ASX/2020-05-01-PXS-Investor-Presentation.pdf

remember this.

LOXL-2
Chronic fibrosis -NASH,IPF, CKD
PXS-5382/PXS5338; Phase 1 trials in 2 compounds complete. Commercial partnering process in progress.
* NASH / Liver Fibrosis; $35b Deutsche Bank market forecast for 2025
* Pulmonary fibrosis (IPF); $3.5b iHealthcareanalyst. Incmarket forecast for 2021
* Kidney fibrosis
* Cardiac fibrosis
http://www.pharmaxis.com.au/assets/Documents/pdf/02020/ASX/2020-05-01-PXS-Investor-Presentation.pdf

if side dish COVID19 was not emerged from kitchen,
a lot of customers would go hungry / with more than half empty stomach after main course COPD interim results.
remember aperitif served as asthma results/AZN

likewise :))

* NSP16 binds mRNA recognition domains of U1/U2 snRNAs and disrupts mRNA splicing
* NSP1 binds in the mRNA entry channel of the ribosome to disrupt protein translation
* NSP8 and NSP9 bind the Signal Recognition Particle and disrupt protein trafficking

* These disruptions to protein production suppress the interferon response to infection
https://www.cell.com/action/showPdf?pii=S0092-8674%2820%2931310-6

Statement of capital following an allotment of shares on 30 September 2020

https://s3.eu-west-2.amazonaws.com/document-api-images-live.ch.gov.uk/docs/vrReQmxm3NkFPArC5occ3a7Pw-WHhv2JPdu67UYKuvw/application-pdf?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=ASIAWRGBDBV3EYRTW2J7%2F20201008%2Feu-west-2%2Fs3%2Faws4_request&X-Amz-Date=20201008T135345Z&X-Amz-Expires=60&X-Amz-Security-Token=IQoJb3JpZ2luX2VjEPH%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCWV1LXdlc3QtMiJHMEUCIQC5gD21Z6OLZll1odDbk55t5I95DpvK5QrSN%2FCqqcjSOwIgexBVO5JxTsF%2BDW8Zw5%2BVZQnjl1LLU5aLB%2FKmoNzAbg4qtAMIKhADGgw0NDkyMjkwMzI4MjIiDD%2B8Yws%2BNq5a8JFvuiqRA5Haajerjv4swAsHj17WZZt6F9qYw0iYh6CWLfwZJTpxrVcdbkaWCH8lA%2BkTAYfBo3Xoo4Ud8nSYZQ2wUnhsF6Yidun934h2LKqh9X0D9YoR%2FCmQhvss6pHRX8%2BfYPnx1n1AUAbMYTVuwgp%2Fy056mz00oAacPy5Q6xa%2Fe9MizmYchnjfYkXqcLV%2BK%2Fk4UW15guyWL0sPN6Qsvr3xl867J1OH6paBl4R7ucl2UwCz809sPJAh1uvF6X3TP%2FO59EScwsDHZyxDYpVf%2FeGa0b3VzuK74N6WKSIDbScfGl8DkQVfe8ageAW5sb6uLDfy8WtZCNBPmDtJDHM0CS2bms8IzaF9UTvIYZT%2F5Opubfei1STBs6TpRJFslYTJ4Pq5Prk6uWaF0uUT4drKMtfE5MvGhzEhNfvqTojxydEFWVkn3CAh8XdL3vmG24BPDbgOd0xtszK3%2FoIUklkjcI%2BUUuV2ViUg9xjOrPPPVhqffhNp0RLKjFc9VCiU9UrZACs5CaC2o6mmRnj9VAL7AiNbXONaL%2BazMOee%2B%2FsFOusBlsyzFM0Y8jTjLgY2j%2FViHcA0DatQm62%2F0DWpjMZVsfzKkOxrlg4tpJ63qc33fFt%2FTq2ArSgrdqs6BQuOeIWYNzLerBATGqDJVeaA46efgcZu4Q5cwvo%2B9Il3g3WZam8v13uqrCT2HLYgoDH%2BXlB05XMBijajZhinE34n8V%2Fz9X%2FKBoHIENBEByroGHETO70%2BUz%2Br197uv4ix4o%2FGxRKjeW3KKnh%2FYi9W%2Fddaj7KbGUndsCD9h%2BBQodfVNwb39XORYxvF9Sv4Dm4NUdVxsGbmhplcxAD2Z16%2Bv06EDR8u2i6%2B0GWQP7XjfVL5cw%3D%3D&X-Amz-SignedHeaders=host&X-Amz-Signature=535b21b133313acb415bbe1347735df16474cf7da2022561c50e796ef830b1c2

Emergex Vaccines Holding Limited (‘Emergex’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T cell immune response, and researchers at the Institute of Technology on Immunobiologicals of the Oswaldo Cruz Foundation (Bio-Manguinhos/Fiocruz), today announce the determination of the MHC CD8 T cell epitope expression library for Fiocruz’s commercial yellow fever vaccine on six major HLA supertypes.
https://www.businesswire.com/news/home/20200818005732/en/Emergex-Bio-ManguinhosFiocruz-Elucidate-Cell-Epitopes-Produced-Commercial

Omid Abbaszadeh, M.D.
@omidabszdh
During recent #SARS-CoV2 pandemic outbreak, in Iran, #MS DMD[Disease-Modifying Drug], Interferon B1 (#ReciGen
Registered sign
, made by Iranian pharmaceutical company, CinnaGen) is widely used to treat #COVID-19 infection in hospitalized patients and also outpatients! Nice results may achieved!
This raises the opinion that COVID-19 presentations should be due to human immune system over-activation, as it happens in #MS.
This may lead to a fantastic therapy window in MS and Covid-19 cure!
9:39 AM · Oct 8, 2020·Twitter for iPad

A theraputic treatment for covid19 may be the only reasonable option

"" All today’s vaccines are death traps when it comes to coronaviruses. No coronavirus vaccines have ever worked.
There is a reason why common cold (caused by coronaviruses) are so common ""

https://insight.jci.org/articles/view/123158
https://twitter.com/flavinkins/status/1313703607330459648

Emergex may be upto something with their CD8+ T-cell programing.
starting the triails for covid19 in Q4 2020.

Ersa Flavinkins
@flavinkins
https://twitter.com/flavinkins/status/1313703607330459648

https://insight.jci.org/articles/view/123158

All today’s vaccines are death traps when it comes to coronaviruses. No coronavirus vaccines have ever worked. Having antibodies is worse than not having them. Wonder why the S NTD exists? To disrupt vaccines. You need special Fc engineering to render
A theraputic antibody safe against a coronavirus without causing catastrophic ADE that raises death rates to 40+%. An effective T cell response need the N protein to be exprpessed within the cells. No current vaccine allow this to happen and T cell response is the only effective
Immunity against coronaviruses. There is a reason why common cold (caused by coronaviruses) are so common

https://zenodo.org/record/3986406#.X3aaBiT92Ef
..............................................................................................................................................................................................................
15th September 2020
** Emergex’s next generation vaccines have been designed to expand the body’s natural immune response by programming CD8+ T-Cells to rapidly recognise and respond to pathogens. This approach is aimed at providing effective prevention of disease while eliminating the allergic, autoimmune or antibody mediated side effects associated with traditional vaccines. Clinical trials of the first Emergex COVID-19 vaccine candidate are intended to start in Q4 2020.

https://emergexvaccines.com/emergex-vaccines-and-george-mason-university-identify-t-cell-epitopes-presented-by-sars-cov-2-infected-cells/

obvious one would be the approval for cov19 treatment.

think, lots of us waiting for same news you pointed

gkb47

what sort of news would please you, apart from the obvious ?